EP 0973904 A1 20000126 - COMPOSITIONS AND USE OF M-CSF-alpha
Title (en)
COMPOSITIONS AND USE OF M-CSF-alpha
Title (de)
Zusammensetzungen und Verwendungen von M-CSF-alpha
Title (fr)
COMPOSITIONS ET UTILISATIONS DE M-CSF-alpha
Publication
Application
Priority
- US 9804802 W 19980304
- US 3858397 P 19970304
Abstract (en)
[origin: WO9839449A1] The invention is a method and composition for reducing a population of diseased cells by administration of a gene delivery vehicle capable of expressing an M-CSF alpha mutant having a decreased capacity to be proteolytically processed and released from a cell membrane. The invention is also a combination of therapeutic agents including gene delivery vehicles expressing M-CSF alpha or an M-CSF alpha mutant in combination, for example, either with a soluble M-CSF, an M-CSF alpha convertase inhibitor, or a gene delivery vehicle expressing prodrug activator such as thymidine kinase followed by administration of the prodrug.
IPC 1-7
IPC 8 full level
A61K 35/76 (2006.01); A61K 38/00 (2006.01); A61K 38/19 (2006.01); A61K 48/00 (2006.01); A61P 35/00 (2006.01); C07K 14/53 (2006.01); C12N 5/10 (2006.01); C12N 15/09 (2006.01); C12N 15/27 (2006.01)
CPC (source: EP)
A61K 38/193 (2013.01); A61P 35/00 (2017.12); C07K 14/53 (2013.01); A61K 48/00 (2013.01); C12N 2799/022 (2013.01); Y02A 50/30 (2017.12)
Citation (search report)
See references of WO 9839449A1
Designated contracting state (EPC)
AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
DOCDB simple family (publication)
WO 9839449 A1 19980911; AU 6458898 A 19980922; EP 0973904 A1 20000126; JP 2001517079 A 20011002
DOCDB simple family (application)
US 9804802 W 19980304; AU 6458898 A 19980304; EP 98910322 A 19980304; JP 53892498 A 19980304